In 2022, IPD initiated a new program aimed at developing an affordable measles and rubella (M/R) vaccine that will be manufactured in Senegal. To achieve this goal, IPD will utilize Batavia Biosciences’ Hip-Vax intensified production process, complying with Good Manufacturing Practice (GMP) standards, for producing measles and rubella material. Univercells Technologies’ NevoLine™ Upstream platform will also be leveraged, to expedite the manufacturing process. The MR project has four primary objectives:

1. to produce the first MR vaccine in Africa according to national quality and regulatory standards, and that has WHO prequalification;
2. to diversify the supplier base for UNICEF procurement and Gavi financing by offering a sustainable product costing less than $1;
3. to collaborate with KU in implementing a conventional lyo MR 5 dose presentation; and
4. to conduct proof of concept studies on novel delivery mechanisms for MR vaccine.

IPD has established a vaccine strategy to diversify its portfolio of vaccine and be better positioned to develop vaccine of interest for the region. As a key component of its strategic goal to establish self-sufficient biomanufacturing capabilities, IPD is working in partnership with the WHO mRNA vaccine technology transfer Hub to obtain this technology. The mRNA platform holds the potential for application in addressing various diseases, thus granting IPD the chance to spearhead pioneering research and cater directly to the healthcare requirements of African populations.

The WHO mRNA technology transfer Hub program is an initiative aiming at sustainably build local production capacity in developing countries through the establishment of a Technology Transfer Center in South. Seven African countries have been selected to receive this technology, including Senegal, which has appointed the Institut Pasteur de Dakar Foundation to carry out this project. More about this programme here.

Launched in 2020 during the Covid-19 lockdown, DIATROPIX‘s mission is to produce affordable diagnostics for neglected epidemics in Senegal through technology transfer. The aim is to address the gaps in the availability, quality, and affordability of diagnostic tests. Currently, DIATROPIX has the capacity to manufacture 2-4 million rapid tests per year. However, their operations are being expanded with the construction of a new semi-automated production site. This new facility will have a total capacity of 50 million rapid tests per year.

Furthermore, DIATROPIX is actively engaged in various programs, including measles and rubella testing, which will contribute to vaccine delivery and support GAVI’s mission.

Under construction in Senegal’s new town of Diamniadio, Madiba is a state-of-the-art facility designed to enable full production and filling of regionally relevant vaccines in Africa. The filling equipment and supply chain have been developed to be broadly suitable for various types of vaccines, including live viral vaccines, mRNA vaccines, and protein-subunit vaccines, with a target capacity of over 300 million doses.

The long-term vision for Madiba is to expand the vaccine portfolio to cover Measles/Rubella, Polio, rotavirus, and develop a cell-culture yellow fever candidate. As the CEPI preferred manufacturer in Africa, IPD will receive the Lassa Fever vaccine candidate for production starting from 2026/27 onwards.

In 1927, IPD discovered the yellow fever virus and has been producing its live attenuated vaccine for 86 years at the historical campus in Dakar. IPD is one of the 4 producers worldwide and the only WHO pre-qualified vaccine manufacturer in Africa. In 2013, IPD initiated the plan to expand its longstanding production unit and the construction of AfricAmaril began on the Diamniadio site in 2019. It is expected to be completed by the end of 2025 and will be operating by mid-early 2026. The new facility will expand production capacity from 3-8m doses per annum to 30m.

IPD has been collaborating with the Ministry of Health since 2012 to enhance influenza sentinel surveillance activities. This syndromic surveillance system, which detected Ebola in Dakar in 2014 and Covid-19 in March 2020, methods by identifying unusual health events earlier, enabling a more prompt public health response. Its scope covers various syndromes linked to febrile pathologies of public health concern in Senegal, such as malaria, arbovirus infections, and diarrhea.

Notably, IPD has played an integral role in the region, providing surveillance and diagnostic support to over 22 African countries during epidemic outbreaks. The 4S Network, consisting of 28 sentinel surveillance sites dispersed across all 14 regions of Senegal, is currently being replicated throughout the ECOWAS region in collaboration with the Africa CDC and the West Africa Health Organization (WAHO).

CARE is being established in Dakar, Senegal, with the goal of efficiently promoting preparedness and response to epidemics. Housed on the campus of the Institut Pasteur de Dakar, CARE will have three main objectives. Firstly, it aims to train the next generation of leaders and front liners who will be deployed on epidemic battlefields. Secondly, CARE will focus on disease intelligence by collecting, storing, and analyzing extensive epidemiological data to predict and anticipate future health threats. Lastly, it will translate research on epidemics into social and business value by fostering an innovative culture and entrepreneurship.

For IPD, the opportunity lies into the African youth. Today, more than 60% of Africa’s population is under 25 and young Africans are expected to constitute 42% of global youth by 2030.

Institut Pasteur de Dakar has launched the Knowledge & Workforce for Africa Manufacturing’s Equity (KWAME) initiative. to ‘accelerate the development of a workforce that is formally trained in Africa through collaborations with African countries and manufacturers and with a long-term vision at the level of the higher education system to support manufacturing projects on the continent’. Through partnerships, KWAME will become a biomanufacturing training hub of excellence for the continent supporting the MADIBA’s ambitions of local production and enabling to manufacture and supply high-quality, affordable and relevant vaccines for Africa in Senegal by training young men and women to new qualified jobs.

The Institut Pasteur de Dakar Medical Biology Laboratory is a biological analysis laboratory open to the general public.

It currently has 2 sampling sites: the Plateau site near the Le Dantec hospital and its annex, and the VDN site near the Dakar trade fair.

We welcome our patients between 7.30 a.m. and 6 p.m. Monday to Friday, and between 7.30 a.m. and 11.30 a.m. on Saturdays.

All analytical parameters are controlled on a daily basis (internal quality control), and the LBM participates in several external quality assessment programs throughout the year for all parameters.

For Many Hospitals, Clinics, Industries, Restaurants, Hotels, Hydraulic agencies we offer a wide range of services such as :

• Dialysis water analysis
• Drinking water
• Catering
• Equipment sterility control
• Air quality in clean rooms
• Surface hygiene (premises and equipment)
• Germ identification
• Water quality,
• Raw materials quality
• Auto control of finished products
• Water circuit monitoring, pool water quality
• Quality of meal monitoring…

Institut Pasteur de Dakar is renowned for its excellent vaccination service and qualified staff. We offer several vaccines for all ages.

Other services:

• Pre-vaccination consultation and post-vaccination follow-up
• Updating of vaccination records
• Preparation of a duplicate in case of lost vaccination booklet Duplicate
• Certificate of contraindication
• Mass vaccination in requesting structures (company, school…) with the possibility of our teams traveling.

Rabies is a viral disease transmitted to humans through the saliva of infected animals (often dogs), when bitten, scratched or licked on injured skin or mucous membranes.

A safe and effective vaccine is available to protect against the disease before exposure, and to treat it afterwards.

Depending on the case, the IPD administers either anti-rabies serum or anti-rabies vaccine.